Open AccessB-Cell Targeted Treatments for Neuromyelitis Optica Spectrum Disorder: A Focus on CD19 and CD20
Author(s) -
Michaël Lévy,
Maureen A. Mealy
Publication year - 2021
Publication title -
immunotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.256
H-Index - 7
ISSN - 2253-1556
DOI - 10.2147/itt.s255722
Subject(s) - neuromyelitis optica , rituximab , medicine , spectrum disorder , cd20 , cd19 , monoclonal , monoclonal antibody , disease , immunology , myelitis , spinal cord , antibody , pathology , psychiatry
Neuromyelitis optica spectrum disorder (NMOSD) is a rare relapsing autoimmune disease of the central nervous system that preferentially targets the optic nerves and spinal cord, leading to visual loss and impaired mobility. Until 2019, no medications were FDA-approved for NMOSD treatment, and standard of care was based on mostly empiric and retrospective data. Therapies that target B cells emerged as a treatment strategy due to their fundamental role in disease pathogenesis. We explore different monoclonal antibodies directed at either CD20+ or CD19+ B cells that may have utilization in the treatment of NMOSD, discussing what is known regarding their efficacy and safety.